Site icon pharmaceutical daily

Tinnitus Pipeline Research Report 2022: Comprehensive Insights About 8+ Companies and 8+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Tinnitus – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The publisher’s, “Tinnitus – Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Tinnitus pipeline landscape.

A detailed picture of the Tinnitus pipeline landscape is provided which includes the disease overview and Tinnitus treatment guidelines. The assessment part of the report embraces, in depth Tinnitus commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinnitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Tinnitus Emerging Drugs Chapters

This segment of the Tinnitus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tinnitus Emerging Drugs

AM-101: Auris Medical

AM-101 is an NMDA receptor antagonist that is being developed for treatment of acute inner ear tinnitus. The NMDA (N-methyl-D-aspartate) receptor is a glutamate receptor on the neuron leading to the auditory cortex that is communicated to by the hair cells of the inner ear. The drug is in Phase III clinical development for the treatment of Tinnitus.

OTO-313: Otonomy

OTO-313 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. It is believed that gacyclidine can reduce the severity of tinnitus symptoms following cochlear injury by decreasing the over-activation of damaged auditory nerve fibers in the cochlea and their connections. OTO-313 utilizes a novel, patent-protected formulation technology to provide several weeks of gacyclidine drug exposure in the inner ear following a single intratympanic injection. In 2020, positive results were reported from a Phase I/II trial of OTO-313 in patients with unilateral tinnitus of at least moderate severity. A Phase II trial is currently underway with results expected in mid-2022. In November 2014, Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus.

Phases

The publisher’s report covers around 8+ products under different phases of clinical development like

Route of Administration

Tinnitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

Products have been categorized under various Molecule types such as

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tinnitus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tinnitus therapeutic drugs key players involved in developing key drugs.

Tinnitus Report Insights

Tinnitus Report Assessment

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jv0584

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version